Watson Pharmaceuticals' has received approval in the USA to marketCondylox Gel 0.5% (podofilox) for the treatment of external genital and perianal warts. The product is expected to be launched in the second quarter of fiscal 1997. Condylox 0.5% Topical Solution has been available in the USA since 1991, with sales of $10 million in 1996. The new product is easier to apply than the solution and is also indicated for perianal warts, says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze